Oxford BioMedica inks deal to make AstraZeneca's potential COVID-19 vaccine

(Reuters) - Britain's Oxford BioMedica has agreed with AstraZeneca to manufacture the drugmaker's experimental COVID-19 vaccine, the cell therapy company said on Thursday.Oxford BioMedica will provide the drugmaker withmultiple batches of the vaccine, called AZD1222, under a one-year clinical and commercial supply agreement, the company said, adding that the majority of it is expected be produced throughout 2020.Oxford BioMedica shares were up 7.3% at 769 pence after the announcement.